Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Ralph Lauren Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.41 (market cap $763.64M), while Ralph Lauren Corp trades at $371.24 (market cap $21.89B). The key difference: Ralph Lauren Corp is far larger — about 28.7× Ginkgo Bioworks Holdings Inc's market cap, and Ralph Lauren Corp pays a 1.09% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Ralph Lauren Corp for 84 Days on average.
| DNA | RL | |
|---|---|---|
Market Cap | $763.64M | $21.89B |
Volume | 3,204,177 | 481,617 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $414.25 |
52-Week Low | $5.48 | $309.29 |
Typical Hold Time | 7 Days | 84 Days |
Enterprise Value | $865.59M | $22.95B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Ralph Lauren (RL) trades at $370.82, up 2.68% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growth to $7.08B in 2025, net income margin of 11.76%, and consistent earnings beats. Recent news highlights dividend declarations, global expansion, and sustainability progress, supporting positive sentiment.
Outlook remains favorable with analyst consensus price target of $456.67 implying 23% upside, though risks include competitive pressures and potential economic slowdown. Earnings momentum and brand strength provide tailwinds, but investors should monitor execution on growth initiatives amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
